Histopathologic Comparison Among Drug Eruptions Induced by Enfortumab Vedotin, Brentuximab Vedotin, and Taxanes.

Microtubule-stabilizing agents (enfortumab vedotin and brentuximab vedotin) and microtubule-disrupting agents (docetaxel and paclitaxel) are used as anticancer agents but can also induce drug eruptions. Recently, mitotic arrest figures have been reported in various non-neoplastic cells as the histopathologic side effect of these drug eruptions. Therefore, we performed a comparative analysis of drug eruptions associated with these microtubule-targeting agents.

Escalating the dose of high-dose-rate brachytherapy combined with external beam radiotherapy improves the disease control rate in patients with high- or very-high-risk prostate cancer.

Purpose: High-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) is an effective treatment for patients with high- and very-high-risk prostate cancer. We sought to identify the factors associated with reduced biochemical recurrence rates following HDR-BT.

Methods: A total of 304 patients with high- or very-high-risk prostate cancer who underwent HDR-BT and EBRT were analyzed.

Non-contrast CT attenuation value of renal papilla is a novel predictor of recurrence in kidney stone disease.

In calcium stone formers, most stones grow attached to Randall's plaque, which can be identified by measuring the computed tomography (CT) attenuation value of renal papilla. We hypothesized that the CT attenuation value of renal papilla can predict the severity (recurrent or multiple stone former) and recurrence of the stone disease. We retrospectively reviewed the charts of 180 calcium oxalate stone formers who underwent non-contrast CT and 24-hour urine chemistry in our hospital between September 2012 and November 2021.

Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.

Background: We compare the oncological outcomes and health-related quality of life (HRQOL) in men with high-risk prostate cancer after robot-assisted radical prostatectomy (RARP) versus that after high-dose-rate brachytherapy + external beam radiotherapy + hormone therapy (hereafter: "HDR+").

Methods: We included 233 men who underwent RARP and 179 men who underwent HDR+ for high-risk prostate cancer at our hospital. We investigated the following oncologic outcomes: time to biochemical recurrence, time to development of castration-resistant prostate cancer (CRPC), cancer-specific survival, and overall survival.

Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.

Background/aim: Pneumonitis during durvalumab consolidation therapy after chemoradiotherapy (CRT) is a major cause of treatment discontinuation. Although previous studies have revealed an association between antinuclear antibody (ANA) positivity and the safety and efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC), there are no reports on durvalumab consolidation therapy. This study investigated the safety and efficacy of durvalumab after CRT in ANA-positive patients.